{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(1)"],"submitter":["Wu C"],"pubmed_abstract":["<h4>Background</h4>Data on fibrinolytic therapy use for ST-segment elevation myocardial infarction (STEMI) and long-term clinical outcomes in developing countries are limited. We aimed to investigate the management and 2-year mortality of fibrinolytic-treated patients in China.<h4>Methods</h4>A total of 19,112 patients with STEMI from 108 hospitals participated in the China Acute Myocardial Infarction registry between January 2013 and September 2014. We investigated the 2-year all-cause mortality among patients treated with fibrinolysis. Non-invasive clinical indexes were used to diagnose successful fibrinolysis or not.<h4>Results</h4>Only 1823 patients (9.5%) enrolled in the registry underwent fibrinolysis and 679 (37.2%) could be treated within 3 h after symptom onset. The overall use of rescue percutaneous coronary intervention was 8.9%. Successful fibrinolysis, which could be achieved in 1428 patients (78.3%), was related to types of fibrinolytic agents, symptom to needle time, infarction site, and Killip class. Follow-up data were available for 1745 patients (95.7%). After multivariate adjustment, successful fibrinolysis was strongly associated with a decreased risk of death compared with failed fibrinolysis at 2 years (8.5% vs. 29.0%, hazard ratio: 0.27, 95% confidence interval: 0.20-0.35).<h4>Conclusion</h4>Within a minority of STEMI patients in the CAMI registry underwent fibrinolysis, most of them could achieve successful clinical reperfusion, presenting a much benign 2-year survival outcome than those with failed fibrinolysis. Quality improvement initiatives focusing on fibrinolysis are warranted to achieve its promise fully.<h4>Trial registration</h4>URL: https// www.<h4>Clinicaltrials</h4>gov . Unique identifier: NCT01874691. Registered 11/06/2013."],"journal":["BMC cardiovascular disorders"],"pagination":["103"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9948459"],"repository":["biostudies-literature"],"pubmed_title":["Fibrinolytic therapy use for ST-segment elevation myocardial infarction and long-term outcomes in China: 2-year results from the China Acute Myocardial Infarction Registry."],"pmcid":["PMC9948459"],"pubmed_authors":["Yang J","Wu C","Xu H","Li L","Zhao Y","Li W","Yang Y","Qiao S","Wang S","Jin C","Zeng J","Gao X","Wang Y"],"additional_accession":[]},"is_claimable":false,"name":"Fibrinolytic therapy use for ST-segment elevation myocardial infarction and long-term outcomes in China: 2-year results from the China Acute Myocardial Infarction Registry.","description":"<h4>Background</h4>Data on fibrinolytic therapy use for ST-segment elevation myocardial infarction (STEMI) and long-term clinical outcomes in developing countries are limited. We aimed to investigate the management and 2-year mortality of fibrinolytic-treated patients in China.<h4>Methods</h4>A total of 19,112 patients with STEMI from 108 hospitals participated in the China Acute Myocardial Infarction registry between January 2013 and September 2014. We investigated the 2-year all-cause mortality among patients treated with fibrinolysis. Non-invasive clinical indexes were used to diagnose successful fibrinolysis or not.<h4>Results</h4>Only 1823 patients (9.5%) enrolled in the registry underwent fibrinolysis and 679 (37.2%) could be treated within 3 h after symptom onset. The overall use of rescue percutaneous coronary intervention was 8.9%. Successful fibrinolysis, which could be achieved in 1428 patients (78.3%), was related to types of fibrinolytic agents, symptom to needle time, infarction site, and Killip class. Follow-up data were available for 1745 patients (95.7%). After multivariate adjustment, successful fibrinolysis was strongly associated with a decreased risk of death compared with failed fibrinolysis at 2 years (8.5% vs. 29.0%, hazard ratio: 0.27, 95% confidence interval: 0.20-0.35).<h4>Conclusion</h4>Within a minority of STEMI patients in the CAMI registry underwent fibrinolysis, most of them could achieve successful clinical reperfusion, presenting a much benign 2-year survival outcome than those with failed fibrinolysis. Quality improvement initiatives focusing on fibrinolysis are warranted to achieve its promise fully.<h4>Trial registration</h4>URL: https// www.<h4>Clinicaltrials</h4>gov . Unique identifier: NCT01874691. Registered 11/06/2013.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-03-18T13:16:17.163Z","creation":"2025-05-29T21:11:47.676Z"},"accession":"S-EPMC9948459","cross_references":{"pubmed":["36814182"],"doi":["10.1186/s12872-023-03105-1"]}}